39581-61-8

Usage

Uses

Used in Fragrance Industry:
Methyl benzofuran-2-acetate is used as a fragrance ingredient for its pleasant, fruity odor that resembles the scent of apricots and cherries. It adds a distinct and appealing aroma to perfumes, colognes, and other scented products.
Used in Flavor Industry:
In the flavor industry, Methyl benzofuran-2-acetate is used as a flavoring agent to impart a fruity taste and aroma to various food and beverage products, enhancing their overall flavor profile.
Used in Essential Oils:
Methyl benzofuran-2-acetate is also used in the formulation of essential oils, where it contributes to the aromatic profile and provides a pleasant scent that can be beneficial in aromatherapy and other applications.

InChI:InChI=1/C11H10O3/c1-13-11(12)7-9-6-8-4-2-3-5-10(8)14-9/h2-6H,7H2,1H3

Upstream product

• 28752-82-1 2-(allyloxy)benzaldehyde 
• 67-56-1 methanol 
• 62119-70-4 benzofuran-2-yl-acetic acid 
• 95-28-3 2-benzofuranacetonitrile 
• 372937-72-9 (3,5-diiodo-4-hydroxybenzoyl)benzofurane-2-propionic acid 
• 40467-01-4 methyl(triphenylphosphoranylidene)acetate 
• 201230-82-2 carbon monoxide 
• 19115-31-2 1-(o-hydroxyphenyl)propargylic alcohol 
• 89-95-2 2-methyl-benzyl alcohol 
• 934569-81-0 2-(1-hydroxy-2-propynyl)-(2-propenyloxy)benzene 

Downstream Products

• 40484-98-8 1-(2-methylbenzofuran-3-yl)ethan-1-one 
• 160420-56-4 [3-(4-methoxy-benzoyl)-benzofuran-2-yl]-acetic acid methyl ester 

Relevant academic research and scientific papers

COMPOUNDS, COMPOSITIONS AND METHODS OF USE AGAINST STRESS GRANULES

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

A novel palladium-catalyzed dicarbonylation process leading to coumarins

(Chemical Equation Presented) A novel approach to coumarin derivatives has been developed starting from readily available 2-(1-hydroxyprop-2-ynyl)phenols, based on an unprecedented palladium-catalyzed dicarbonylation process. Reactions were carried out in

ANTIARRHYTHMIC PRECURSOR COMPOUNDS, METHODS OF SYNTHESIS AND METHODS OF USE

The invention comprises compounds of Formula 1: wherein, R1 is independently H or halogen; R2 is, for example, H or -R10-NR11R12, and wherein R10 is C1-C6 alkyl, and R11 and Rsu

Cascade reactions: Sequential homobimetallic catalysis leading to benzofurans and β,γ-unsaturated esters

The concatenation between a Pd(0)-promoted deallylation catalytic cycle and a Pd(II)-promoted heterocyclization catalytic cycle (an example of what we have named "sequential homobimetallic catalysis") has been shown to occur starting from 1-(2-allyloxyphenyl)-2-yn-1-ols 1 to afford 2-benzofuran-2- ylacetic esters 2 and β,γ-unsaturated esters in high yields under carbonylative conditions. In view of the conceptual as well as the synthetic importance of the process, the mechanistic aspects and the synthetic scope of the reaction have been investigated in detail. All the experimental evidence is in agreement with the sequential homobimetallic mechanism, and the reaction has proven to be of general synthetic applicability.

Photochromic heterocyclically anellated indenochromene compounds

The present invention relates to specific photochromic heterocyclically annellated indenochromene derivatives and the use thereof in plastics of all types, particularly for ophthalmic applications. In particular, the present invention relates to indeno[2,1-f]chromene derivatives having the following general formula (I) and indeno[1,2-h]chromene derivatives having the following general formula (II):

Enantiomeric compounds for treatment of cardiac arrhythmias and methods of use

The subject invention pertains to novel enantiomerically pure compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making and purifying the compounds. The enantiomerically purified compounds, and compositions of these compounds, exhibit unexpectedly distinct and advantageous characteristics, such as a markedly superior ability to reduce or inhibit ventricular premature beats, as compared to racemic mixtures of the compounds.

Compounds for treatment of cardiac arrhythmia synthesis, and methods of use

The subject invention pertains to novel compounds, and compositions comprising the compounds, for the treatment of cardiac arrhythmias. The subject invention further concerns a method of making the novel compounds. The novel compounds are rapidly metabolized analogs of amiodarone, having the distinct and advantageous characteristic of being metabolized to a less lipophilic compound. The new compounds can have particular utility for treating life-threatening ventricular tachyarrhythmias, especially in patients with congestive heart failure (CHF). The product can also provide effective management for ventricular arrhythmias and supraventricular arrhythmias, including atrial fibrillation and re-entrant tachyarrhythmias involving accessory pathways.

Peripherally selective kappa opioid agonists

PCT No. PCT/US98/06485 Sec. 371 Date Jun. 24, 1999 Sec. 102(e) Date Jun. 24, 1999 PCT Filed Apr. 2, 1998 PCT Pub. No. WO98/49158 PCT Pub. Date Nov. 5, 1998The compounds of the instant invention as those of Formula I or a pharmaceutically acceptable salt t

Certain benzofuranyl-N-[pyrrolidin-1-YL]-N-methyl-acetamide derivatives useful as opioid agonists

PCT No. PCT/US98/07832 Sec. 371 Date Jun. 30, 1999 Sec. 102(e) Date Jun. 30, 1999 PCT Filed Apr. 17, 1998 PCT Pub. No. WO98/49141 PCT Pub. Date Nov. 5, 1998The novel compounds of formula (I) of the instant invention are selective kappa opioid agonists use

Compound for treatment of cardiac arrhythmia, synthesis, and methods of use

Described is a novel compound and method, useful for treatment of cardiac arrhythmias, especially useful in patients with congestive heart failure (CHF). A process for synthesizing the novel compound is also described.